Collaboration Details

Print  Close

Title of Collaborative Activity:

Safety and Efficacy Evaluations of Topical Microbicide (TM)/Biomedical Prevention (BP) Products in the Repeat Low-Dose Macaque SIV/SHIV Infection Model

Description of Collaborative Activity:

The NIAID and CDC recognize the need to perform preclinical safety and efficacy evaluations of candidate products in the repeat low-dose (RLD) macaque SIV/SHIV infection model that has been established by CDC. NIAID established an interagency agreement with CDC in order to: 1) conduct safety and efficacy evaluations of TM/BP products in the RLD macaque model -- including pharmacokinetic/pharmacodynamic analyses of candidate biomedical prevention products; 2) utilize relevant macaque species, virus strains, and routes of infection to accomplish the proposed evaluations; and 3) perform other macaque studies as needed.

Type of Collaborative Activity:

Select Type of Collaborative Activity

Year the Collaborative Activity Originated:


NIH Participating Institutes/Centers/Office of the Director:


HHS Agency Collaborators on this Activity: